more
professional-bg-img

Devon W. Edwards is a partner in the Intellectual Property Department.  His practice focuses primarily on district court and appellate patent, trade secret, copyright, and trademark litigation.  Devon litigates and counsels clients across a variety of technologies, including life sciences, high tech, and industrial products.  He has experience representing clients in both bench and jury trials, as well as in PTAB and ITC proceedings and in appeals before the Federal Circuit.  

Experience

Devon is a member of the New York Intellectual Property Law Association.

  • U.S. Supreme Court Upholds Assignor Estoppel Doctrine, But With Certain Limits, Willkie Client Memo (July 1, 2021)
  • Supreme Court Finds Google’s Copying of Java APIs To Be Permitted Fair Use, Willkie Client Memo (April 7, 2021)
  • The Bio-Quarterly: Willkie’s Biologics and Biosimilars Newsletter, February 2021
  • The Bio-Quarterly: Willkie’s Biologics and Biosimilars Newsletter, November 2020
  • Ninth Circuit Reverses Lower Court in FTC v. Qualcomm, Distinguishing “Hypercompetitive Behavior” From Antitrust Violations, Willkie Client Memo (August 24, 2020)
  • The Bio-Quarterly: Willkie’s Biologics and Biosimilars Newsletter, July 2020
  • Willkie Obtains Significant Victory for Hospira in Pharmaceutical Patent Litigation, April 6, 2020
  • The Bio-Quarterly: Willkie’s Biologics and Biosimilars Newsletter, April 2020
  • The Bio-Quarterly: Willkie’s Biologics and Biosimilars Newsletter, January 2020
  • The Bio-Quarterly: Willkie’s Biologics and Biosimilars Newsletter, October 2019
  • The Bio-Quarterly: Willkie’s Biologics and Biosimilars Newsletter, July 2019
  • The Bio-Quarterly: Willkie’s Biologics and Biosimilars Newsletter, April 2019
  • The Bio-Quarterly: Willkie’s Biologics and Biosimilars Newsletter, October 2018
  • The Bio-Quarterly: Willkie’s Biologics and Biosimilars Newsletter, July 2018
  • The Bio-Quarterly: Willkie’s Biologics and Biosimilars Newsletter, January 2018
  • The Bio-Quarterly: Willkie’s Biologics and Biosimilars Newsletter, October 2017
  • Supreme Court Ruling in TC Heartland Revives Focus on the Corporate “Place of Business,” Willkie Client Memo (May 25, 2017)
  • Edwards Lifesciences v. Cardiovalve – Successfully defended medical device patent against IPR challenge before PTAB and achieved affirmance in Fed. Cir.
  • GoTV v. Netflix – Represented Netflix at jury trial in N.D. Cal. against patent assertion entity seeking more than $300 million; jury returned verdict of $2.5 million in damages
  • F45 v. Body Fit Technologies – Prevailed at summary judgment that asserted patent was invalid in competitor vs. competitor action before Judge Bryson (Fed. Cir.) sitting by designation in D. Del.
  • Belcher v. Hospira (epinephrine) – Achieved judgment of non-infringement, invalidity, unenforceability, and award of attorney fees following bench trial in Hatch-Waxman case before Judge Stark (D. Del.), and affirmance in Fed. Cir.
  • Insurent v. Hanover Insurance – Prevailed at summary judgment on all claims, including copyright infringement and trade secret misappropriation, in S.D.N.Y.
  • Merck v. Amneal (mometasone furoate) – Achieved Fed. Cir. affirmance of district court judgment of non-infringement in appeal of Hatch-Waxman action.
     

Credentials

Education


New York University School of Law, J.D., 2015 Pennsylvania State University, B.A., 2012

Bar Admissions


New York, 2016